Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $4.4 million.

  • Spyre Therapeutics' Change in Accured Expenses fell 4011.68% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 105627.18%. This contributed to the annual value of $14.6 million for FY2024, which is 39869.15% up from last year.
  • Spyre Therapeutics' Change in Accured Expenses amounted to $4.4 million in Q3 2025, which was down 4011.68% from -$2.3 million recorded in Q2 2025.
  • Over the past 5 years, Spyre Therapeutics' Change in Accured Expenses peaked at $14.9 million during Q4 2024, and registered a low of -$15.8 million during Q2 2024.
  • For the 5-year period, Spyre Therapeutics' Change in Accured Expenses averaged around $242842.1, with its median value being $450000.0 (2022).
  • Over the last 5 years, Spyre Therapeutics' Change in Accured Expenses had its largest YoY gain of 176846.24% in 2024, and its largest YoY loss of 84900.28% in 2024.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Change in Accured Expenses stood at $455000.0 in 2021, then dropped by 1.1% to $450000.0 in 2022, then crashed by 298.0% to -$891000.0 in 2023, then surged by 1768.46% to $14.9 million in 2024, then crashed by 70.33% to $4.4 million in 2025.
  • Its last three reported values are $4.4 million in Q3 2025, -$2.3 million for Q2 2025, and -$6.0 million during Q1 2025.